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ABSTRACT  
Ambient air pollution and temperature have been linked with cardiovascular morbidity 
and mortality. Metabolic syndrome and its components—abdominal obesity, elevated 
fasting blood glucose, low high-density lipoprotein cholesterol, hypertension and 
hypertriglyceridemia—predict cardiovascular disease, but the environmental causes are 
understudied. This study prospectively examined the long-term associations of air 
pollution, defined as fine-particulate matter with diameter !2.5"m (PM2.5), and 
temperature on the development of metabolic syndrome and its components. Using 
covariate-adjusted Cox-models, we estimated associations of annual mean PM2.5 and 
temperature with incident risk of metabolic dysfunctions in 587 elderly Normative Aging 
Study men (mean (SD), 70 (7) years) between 1993-2011. A 1-µg/m3 annual PM2.5 
increase was associated with higher risk of developing metabolic syndrome (Hazard 
ratio [HR]=1.27, 95% Confidence Interval (CI): 1.06, 1.52), elevated fasting blood 
glucose (HR=1.20, 95%CI: 1.03, 1.39) and hypertriglyceridemia (HR=1.14, 95%CI:1.00, 
1.30). Metabolic syndrome and high fasting blood glucose findings remained significant 
in PM2.5 levels below the U.S. Environmental Protection Agency’s limit (12-µg/m3). A 1-
Cº annual temperature increase was associated with greater elevated fasting blood 
glucose risk (HR=1.33, 95%CI: 1.14, 1.56). Men living in neighborhoods with worse air 
quality—i.e., with higher PM2.5 levels and/or warmer than average—showed increased 
risk of developing metabolic dysfunctions 
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Glossary:  
Body mass index       BMI 
Confidence Interval        CI  
C-reactive protein        CRP 
Hazard ratio         HR  
High-density Lipoprotein       HDL  
Homeostatic model assessment of insulin resistance   HOMA-IR 
Interleukin 6         IL-6 
Metabolic Equivalent hours      MET-hr  
Moderate Resolution Imaging Spectroradiometer   MODIS  
Nitric oxide        NO 
Nitric oxide synthetase      NOS  
Nitrogen dioxide        NO2 
Normative Aging Study       NAS  
Particulate matter        PM 
Particulate matter with diameter under 2.5 µm    PM2.5  
Particulate matter with diameter under 10 µm    PM10  
Plasminogen activator inhibitor type 1     PAI-1 
Reactive Oxygen Species       ROS  
Standard Deviation        SD  
Tumor necrosis factor-#       TNF𝛼  
Very-low-density lipoprotein     VLDL 
Veteran Affairs        VA 
White blood cell       WBC 
 
 
 
 
 
 
 
Introduction: 
Definition and Utility of Metabolic Syndrome 
Metabolic syndrome is an urgent public health concern.  It affects 10-25% of the global 
population and is associated with increased risk of total mortality; cardiovascular 
disease; cardiovascular disease-related mortality; type-2 diabetes mellitus; chronic 
kidney disease; liver disease; asthma; sleep apnea; and selected malignancies.1,2,3,4,5  
  
Initially, several professional organizations endorsed slightly different diagnostic criteria 
for metabolic syndrome, causing inconsistency across studies.6,7,8  In 2009, a joint 
interim task force, comprising representatives from the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and 
Blood Institute; American Heart Association; World Heart Federation; International 
Atherosclerosis Society; and International Association for the Study of Obesity, 
convened to unify the diagnostic criteria.9 
  
For the purposes of this paper, metabolic syndrome is defined in accordance with the 
unified criteria agreed upon by the joint interim task force.  Diagnosis of metabolic 
syndrome is established by having at least three of the following five conditions: 
abdominal obesity (waist circumference $102 cm for men); hypertriglyceridemia ($150 
mg/dl or drug treatment for elevated triglycerides); reduced high-density lipoprotein 
(HDL) cholesterol (<40 mg/dl for men or drug treatment for low HDL cholesterol); 
hypertension (systolic blood pressure $130 mm Hg or diastolic blood pressure $85 mm 
Hg or drug treatment for elevated blood pressure); and high fasting blood sugar ($100 
mg/dl or drug treatment for elevated blood glucose) (TABLE 1).8,9 
  
The confluence of three of these conditions increases cardiovascular and type-2 
diabetes mellitus risk, over and above the risk associated with the individual disorders 
alone.10  Specifically, metabolic syndrome carries a five-fold greater type-2 diabetes 
mellitus risk and a two-fold higher cardiovascular disease risk within five-ten years.9  
Compared to individuals without metabolic syndrome, individuals with metabolic 
syndrome are two-four times more likely to have a stroke; three-four times more likely to 
suffer a myocardial infarction; and twice as likely to die from a cardiovascular episode, 
even controlling for previous cardiovascular event history.11   
  
Despite these findings, the predictive value of metabolic syndrome compared to its 
individual components is controversial.12  Several studies cast doubt on its relative 
prognostic utility.  For example, the San Antonio Heart Study, a cohort study of 2,815 
subjects, demonstrated similar cardiovascular disease and all-cause mortality risk 
among individuals with metabolic syndrome (HR: 2.53; 95% CI: 1.74 to 3.67, HR: 1.47; 
95% CI: 1.13 to 1.92, respectively) and individuals with impaired fasting blood glucose 
(HR: 2.87; 95% CI: 1.96 to 4.20, HR: 1.89; 95% CI: 1.41 to 2.52, respectively) when 
controlling for age, gender and ethnic group.13  Additionally, in a prospective study of 
5128 men aged 40 to 59 without history of cardiovascular disease or type-2 diabetes 
mellitus, the Framingham Risk Calculator outperformed metabolic syndrome in 
predicting coronary heart disease and stroke.14  Arguably, metabolic syndrome’s main 
utility is not its prognostic value, but rather, its grouping of conditions with a shared 
underlying pathophysiology that exert effects through common metabolic pathways.12  
As a result, metabolic syndrome is a useful concept for gaining a better understanding 
of the pathophysiology of the metabolic dysfunction that confers heightened 
cardiovascular disease and mortality risk. 
  
Metabolic Syndrome Epidemiology 
Many factors are believed to modify metabolic syndrome risk, including: genetics; diet; 
activity level; smoking status; family history of diabetes mellitus; education; sex; age; 
race; ethnicity; socioeconomic status; and urban versus rural environment.11 Metabolic 
syndrome increases with age, with 18.3% of individuals aged 20-39 years and 46.7% of 
those over 60 years meeting diagnostic criteria.15  In the United States, metabolic 
syndrome affects an estimated 47-68 million people, with males 60 years or older 
among those at greatest risk.16,17,18 Metabolic syndrome also varies slightly by 
race/ethnicity.  Hispanics have the highest prevalence (35.4%; 95% CI, 34.2%-36.6%), 
followed by non-Hispanic whites (33.4%; 95% CI, 32.6%-34.2%) and blacks (32.7%; 
95% CI, 31.5%-33.9%).15 
  
Metabolic Syndrome Pathogenesis 
Low-grade inflammation is thought to contribute both to the pathogenesis of metabolic 
syndrome and to the subsequent development of cardiovascular disease.19,20  Several 
large population-based cohort studies, including the Framingham Heart Study; the 
Atherosclerosis Risk in Communities Study; and the Women’s Health Initiative 
Observational Study support this link by demonstrating associations between 
inflammatory markers, such as elevated white blood cell count, and increased long-term 
cardiovascular disease risk.21,22,23 
  
Since evidence supports the role of low grade inflammation in the genesis of metabolic 
syndrome, it is unsurprising that various risk factors appear to increase metabolic 
syndrome risk by inducing an inflammatory state.  For example, one hypothesized 
mechanism by which obesity enhances metabolic syndrome risk is the release of pro-
inflammatory cytokines.20,24 Visceral fat is thought to have endocrine function by 
secreting bioactive substances called adipocytokines.20,25  In healthy states, pro-
inflammatory and anti-inflammatory cytokines are intricately balanced.  In obese states, 
adipocytes undergo hypertrophy and hyperplasia.20 As the adipocytes enlarge, blood 
supply may be compromised, leading to hypoxia. In turn, hypoxia causes cell necrosis 
and macrophage infiltration into the adipose tissue, creating an inflammatory state.  
Excess visceral adipose tissue causes dysregulation of the careful balance between 
pro- and anti-inflammatory cytokines. The visceral adipocytes overproduce pro-
inflammatory cytokines, including tumor necrosis factor-# (TNF𝛼); plasminogen activator 
inhibitor type 1 (PAI-1); and heparin binding epidermal growth factor-like growth factor; 
and underproduce anti-inflammatory cytokines, such as adiponectin.25 This 
dysregulation in favor of an inflammatory state is thought to contribute to the 
development of insulin resistance, metabolic syndrome and cardiovascular disease.25 
  
How do these cytokines contribute to metabolic syndrome?  Evidence suggests that 
TNF𝛼, one of the pro-inflammatory cytokines overproduced by visceral adipocytes in 
obesity, has paracrine activity, reducing insulin sensitivity in surrounding adipocytes by 
inhibiting the insulin receptor substrate 1 signaling pathway.11 This inhibition of insulin 
signaling could directly contribute to insulin resistance.  Research in mice showing that 
neutralization of TNF𝛼 with a soluble TNF𝛼 receptor leads to greater insulin sensitivity 
further supports this conclusion.26 Although TNF𝛼 neutralization in humans has not 
been shown to improve insulin sensitivity, the above results indicate TNF𝛼 and other 
inflammatory mediators are likely involved in the generation of insulin resistance.11  The 
positive association between plasma TNF𝛼 and body mass index (BMI), white blood cell 
count and triglycerides, and the negative association between plasma TNF𝛼 and HDL 
cholesterol, provides additional evidence of TNF𝛼’s role in metabolic syndrome.11 
  
Interleukin 6 (IL-6), which is secreted by adipose tissue and skeletal muscle cells, has 
several important systemic actions that also increase metabolic syndrome risk.  
Elevated levels of IL-6 have been associated with higher BMI; reduced HDL cholesterol; 
elevated fasting insulin; and increased risk of type-2 diabetes mellitus.11 IL-6 likely 
exerts its effects through several mechanisms. It acts on the hypothalamus to regulate 
appetite and energy intake, and is involved in hepatic production of C-reactive protein 
(CRP), an acute phase reactant that is released in inflammatory states.11 Additionally, 
IL-6 suppresses lipoprotein lipase, the rate-limiting enzyme that removes triglycerides 
from circulation. IL-6-induced lipoprotein lipase suppression may partially explain 
metabolic syndrome’s elevated triglycerides and low HDL cholesterol, since other 
defects that cause lipoprotein lipase deficiency have been associated with severe 
hypertriglyceridemia; increases in chylomicrons and very-low-density lipoproteins 
(VLDLs); and low HDL cholesterol levels.27  
  
Not only do TNF𝛼 and IL-6 directly induce inflammatory states; they also indirectly 
increase inflammation by inhibiting adiponectin.11  Adiponectin, an anti-inflammatory 
cytokine, is a marker of insulin sensitivity.  Low adiponectin levels are associated with 
insulin resistance; increased BMI; dyslipidemia; hypertension; elevated inflammatory 
markers; and greater cardiovascular disease risk.28,29  IL-6 and TNF𝛼 therefore increase 
metabolic syndrome risk by directly exerting their own disruptive effects and by 
decreasing the protective effects of adiponectin. 
  
Reactive oxygen species—oxygen free radicals formed as byproducts of mitochondrial 
oxidative metabolism and through several other mechanisms—are also implicated in 
metabolic syndrome risk. Reactive oxygen species are important signaling molecules 
and are part of the immune system’s antimicrobial defenses.  However, their excess 
production can damage cells.  High levels of reactive oxygen species are seen in 
chronic diseases.30 Research now suggests that reactive oxygen species may induce 
the production of inflammatory cytokines.30  Reactive oxygen species have also been 
implicated in worsening insulin resistance by activating protein kinases, c-Jun N-
terminal kinase (JNK) and IKK%, which are thought to be key contributors to the 
development of insulin resistance in obesity and diabetes mellitus.31   
  
Reactive oxygen species can also lead to hypertension by increasing vascular tone due 
to the inhibition of nitric oxide (NO), an important mediator of vasodialation. NO 
bioavailability is decreased by superoxide radical overproduction, because NO binds to 
the superoxide radical to generate peroxynitrate.32 (Insulin resistance also exacerbates 
NO reduction, since inhibition of Akt, an intermediate in the insulin pathway, leads to 
inhibition of nitric oxide synthetase (NOS) TNF-# further inhibits NOS expression).32  
Decreased NO bioavailability increases vascular tone and decreases vascular reactivity.  
Reactive oxygen species are additionally implicated in dyslipidemia, by causing 
increased very low-density lipoprotein secretion from the liver. 
  
Other metabolic syndrome risk factors appear to act through similar mechanisms. 
Studies suggest that a high-fat diet, another metabolic syndrome risk factor, may 
similarly increase metabolic syndrome risk through inflammation and reactive oxygen 
species.  In one study, following an overnight fast, Aljada et al. (2004) gave an 
experimental group of nine normal-weight participants a 900-calorie meal from a fast-
food restaurant and a control group of eight normal-weight participants 300 ml of 
water.24 They then measured the level of reactive oxygen species and inflammation in 
blood samples at zero, one, two and three hours after the meal. Among those who had 
consumed the high-calorie meal, they found significant increases in reactive oxygen 
species generation and inflammation via greater expression of C-reactive protein and 
the pro-inflammatory transcription factor, nuclear factor kappa-beta (NF𝜅B).  There was 
no change in reactive oxygen species or inflammatory markers among subjects who 
drank 300 ml of water.   
  
In another, similar study, a 75-g glucose challenge was associated with increased 
leukocyte production of superoxide, a reactive oxygen species.33 Conversely, 
decreasing macronutrient intake in obese subjects by 1000 kcal/day for one month 
resulted in decreased mediators of oxidative stress and inflammation.34  Importantly, 
unlike an isocaloric fast-food meal, a 900-kcal meal based on the American Heart 
Association Step 2 Diet, which is rich in fruit and fiber, does not cause oxidative stress 
and inflammation.35  Therefore, diets high in fat and low in fruits and fiber may increase 
metabolic syndrome risk by increasing systemic inflammation and reactive oxygen 
species production. 
  
Taken together, it appears that multiple metabolic syndrome risk factors, including 
obesity and high-fat diets, induce a pro-inflammatory state. This pro-inflammatory state 
causes insulin resistance, a condition that underlies and drives metabolic syndrome. 
Although over-nutrition and obesity are likely the most important factors in the 
development of metabolic syndrome, other factors that induce inflammation may also 
play a role. 
  
Metabolic Syndrome and the Environment 
Metabolic syndrome rates are increasing worldwide and show geographical variations, 
largely due to lifestyle, socioeconomic, and ethnic differences.36,37,38  However, local 
environmental conditions might also contribute to variations in metabolic syndrome 
rates.39 Air pollution—including atmospheric particulate matter with diameter !2.5 "m 
(PM2.5)—and outdoor temperature are two essential environmental factors that have 
been shown in in-vitro and experimental studies to affect cellular and systemic 
metabolic processes.40,41 
  
PM2.5 is generated via combustion reactions, including automobile exhaust; wood and 
coal combustion; and industrial emissions. Due to PM2.5 particles’ small size, they 
penetrate deep into the lungs and cause inflammation, and are thought to be of greater 
health significance than larger air particles.42,43 According to a systemic analysis for the 
Global Burden of Disease Study 2010, assessing the comparative risk of 67 risk factors, 
ambient particulate matter pollution is ranked ninth as a contributing factor to the overall 
global burden of disease.44 
  
Several epidemiological studies indicate possible associations between air pollutants 
and components of metabolic syndrome.45,46,47,48,49,50 In one of the first studies of the 
topic, Brook et al. (2008) investigated the link between diabetes mellitus prevalence and 
nitrogen dioxide (NO2), a marker of traffic-related air pollution.45 After controlling for 
age, body mass index, and neighborhood income, the data showed a significant 
association between NO2 exposure and diabetes in women, but not in men. This study 
supports the association between exposure to traffic-related air pollutants and the 
prevalence of diabetes mellitus in women. 
  
Further research by Brook and colleagues examined whether long-term exposure to 
ambient particulate matter (PM) increases risk of diabetes-associated mortality.51 Using 
a prospective cohort analysis of 2.1 million Canadian adults from the 1991 Canadian 
census mortality follow-up study, the researchers gathered mortality information from 
the Canadian Mortality Database from 1991-2001. Long-term PM2.5 exposure was 
estimated from satellite data. The data revealed a relationship between long-term PM2.5 
exposure and increased diabetes-related mortality. Specifically, a 10-"g/m3 PM2.5 
exposure increase was associated with a 1.49 increase in the risk for diabetes-related 
mortality (95% CI, 1.37–1.62). 
  
Research suggests that PM2.5 may increase the risk of developing other components of 
metabolic syndrome as well.  One case-control study examined the serum lipid levels of 
236 policemen, half of whom performed traffic-related duties and half of whom worked 
in an office.52 The groups were matched on age and length of service. The policemen 
who were exposed to traffic had significantly worse HDL cholesterol and triglyceride 
levels than the control group that worked in an office. This study supports the 
hypothesis that PM2.5 exposure may increase the risk of dyslipidemia. 
  
Another research group analyzed health data from the Taiwanese Survey on 
Prevalence of Hyperglycemia, Hyperlipidemia, and Hypertension (TwSHHH) to 
determine whether acute PM smaller than 10&µm (PM10)-exposure levels were 
associated with metabolic dysfunction.46 The data indicated that one-day PM10 levels 
were negatively associated with HDL-cholesterol and positively associated with systolic 
blood pressure. Average PM10 levels three days prior to the assessment were positively 
associated with Hemoglobin A1c levels, but not with fasting glucose.46 These data 
support the link between PM exposure and several components of metabolic syndrome, 
including dyslipidemia, hypertension and insulin resistance. 
  
Animal studies further support the causal relationship between PM2.5 exposure and 
metabolic dysfunction. In one such experiment, Sun et al. (2005) exposed 
apolipoprotein E-null mice on a high-fat diet to either concentrated PM2.5 or filtered air 
for six months.53 The high-fat diet mice exposed to PM2.5 vs. filtered air had a 1.5-fold 
increase in atherogenesis; showed signs of endothelial dysfunction, including 
exaggerated vasoconstriction in response to phenylephrine challenge; and displayed 
evidence of vascular inflammation—all key elements suggesting metabolic dysfunction. 
  
To elucidate the mechanism by which PM might contribute to the development or 
worsening of cardiovascular disease, several studies examined the association between 
PM and inflammatory markers.  Inflammatory markers were chosen, because 
inflammation appears to be an important factor in the development of atherosclerosis, 
which is the primary cause of cardiovascular disease, as detailed in the above section.54  
Several studies report associations between short-term ambient PM elevations and 
elevated inflammatory markers, including white blood cell (WBC) count and C-reactive 
protein.54,55,56 Additionally, Chen & Schwartz (2008) found a graded-association 
between long-term PM exposure and inflammatory markers, as evidenced by increased 
WBC count.57 
  
Experimental studies conducted in mice nicely demonstrate the association between 
PM2.5 exposure and inflammation. Sun et al. (2009) advanced their initial research by 
demonstrating that long-term PM2.5 exposure leads to systemic inflammation; increased 
visceral adiposity; and insulin resistance in male mice on a high-fat diet.58 Circulating 
TNF𝛼, PAI-1, and IL-6 levels were increased in the mice exposed to PM2.5, indicating 
that PM2.5, like obesity (as discussed above), may mediate metabolic syndrome risk 
through these cytokines.  PM2.5 exposure also caused several signaling abnormalities 
associated with insulin resistance in the mice, including impaired insulin signaling and 
elevated protein kinase C expression. The same researchers showed that long-term 
PM2.5 exposure causes up-regulation of genes involved in lipogenesis; lipolysis; 
adipocyte differentiation; and lipid droplet formation in mouse adipose tissue.59  A recent 
study demonstrated similar results. Cui et al. (2015) exposed male mice to intranasal-
distilled PM for one month.60 Levels of serum TNF-𝛼 and intracellular reactive oxygen 
species formation were then obtained.  The researchers found that PM exposure 
significantly increased reactive oxygen species production and circulating TNF-𝛼 levels, 
providing additional evidence of the role of oxidative stress and inflammation in PM2.5-
induced metabolic syndrome risk. Taken together, these studies suggest possible 
mechanisms for how PM2.5 might induce metabolic dysfunction.  
  
PM2.5 likely increases metabolic syndrome risk through other mechanisms, in addition to 
inflammation. Endothelial dysfunction is another pathway by which ambient air pollution 
may exacerbate metabolic syndrome risk. Plasma nitrite, the oxidation product of NO, is 
a known marker of endothelial dysfunction. Rutgers University researchers found that 
students exposed to higher levels of PM2.5 in the 24 hours preceding blood collection 
had higher plasma nitrite concentrations.61  Acute PM2.5 exposure appears to induce 
endothelial dysfunction, as evidenced by elevated NO. Other studies further support 
these results. In one double-blind, randomized, cross-over study, 30 healthy men 
inhaled either dilute diesel exhaust or filtered air for one hour.62 The subjects had 
impaired regulation of vascular tone and endogenous fibrinolysis after exposure to dilute 
diesel exhaust.  This endothelial dysfunction may contribute to the development of 
hypertension. 
  
Indeed, acute exposure to PM2.5 appears to elevate blood pressure. In a study of 23 
healthy adults, researchers found that acute exposure to ambient particles mixed with 
ozone induced a 6-mmHg increase in diastolic blood pressure.63  A similar study of 62 
adults with heart disease demonstrated a direct positive relationship between increased 
blood pressure and ambient PM levels.64 Although several mechanisms may contribute 
to this association, PM2.5-induced endothelial dysfunction likely plays a role. 
  
The sympathetic nervous system may also be involved in PM2.5-induced metabolic 
syndrome risk.  In one study, 25 healthy, rural-dwelling adults were exposed to urban air 
pollution for four to five hours/day on five consecutive days.65 Participants’ insulin 
sensitivity was assessed seven days prior to urban pollution exposure; on day five of 
the exposure; and seven days after the final exposure day.  Sympathetic nervous 
system activity was assessed by heart rate variability (decreased variability indicates a 
shift in balance towards sympathetic activity and away from parasympathetic activity).  
PM2.5 levels were obtained at the urban exposure site and at monitors near subjects’ 
homes. Study results demonstrated that a 10 µg*m'3 increase in sub-acute PM2.5 
exposures was associated with increased insulin resistance, as assessed by the 
homeostatic model assessment of insulin resistance (HOMA-IR), and reduced heart 
rate variability. Further analysis indicated that the association between PM2.5 and insulin 
sensitivity is partially explained by lower heart rate variability. These results support the 
hypothesis that the connection between air pollution and metabolic syndrome may be 
partially explained by parasympathetic withdrawal/sympathetic activation. 
  
Induction of hypothalamic inflammation is also a possible mechanism by which PM2.5 
may exert its influence.  Hypothalamic inflammation has been implicated in dysfunction 
in sensing fuel; controlling energy intake; and expending energy in diet-induced 
obesity.66   
  
In research conducted by Liu et al. (2014), mice that were genetically susceptible to 
type-2 diabetes mellitus were exposed to four-to-eight weeks of concentrated PM2.5 or 
filtered air.66  During this period, the mice received either no treatment; intra-
cerebroventricular TNF# antibody (infliximab); or intra-cerebroventricular IKK% inhibitor 
(IMD-0354). IKK% is an enzyme involved in triggering immune response in the 
hypothalamus.  Accordingly, inhibition of IKK% blocks this inflammatory response. 
  
During the study period, Liu et al. (2014) evaluated glucose tolerance; insulin sensitivity; 
and energy homeostasis, operationalized as oxygen consumption and heat 
production.66  At the conclusion of the study, the mice were sacrificed and blood, 
spleen, visceral adipose tissue and the hypothalamus were collected to measure 
inflammatory cells.  Consistent with prior research, PM2.5 exposure was shown to 
induce hyperglycemia; insulin resistance; and elevated hypothalamic IL-6, TNF𝛼 and 
IKK% mRNA expression. Mice who received intra-cerebroventricular IKK% inhibitor (IMD-
0354) displayed improved glucose tolerance; insulin sensitivity; energy homeostasis; 
and decreased peripheral inflammatory response to PM2.5. Intra-cerebroventricular 
TNF# inhibition provided no such benefits. 
  
A recent study found similar results for the protective effect of IKK inhibition in 
preventing PM2.5-exacerbated cardiac damage in mice with type-2 diabetes mellitus.67  
These studies support the hypothesis that PM’s inflammatory effects—specifically, the 
hypothalamic inflammatory response—may represent one mechanism by which PM 
causes metabolic dysfunction.  Research also indicates that individuals with specific 
baseline metabolic dysfunctions—including obesity;68,69,70 hypertension;54,71,72 and 
diabetes mellitus72,73—may be particularly vulnerable to PM-induced cardiac disease. 
  
Temperature is another environmental factor that has been associated with increased 
cardiac morbidity and mortality.74 Prior studies have not explored the relationship 
between temperature and metabolic syndrome.   However, studies have examined the 
association between temperature and individual components of metabolic syndrome. 
The Diabetes study, a nationwide, population-based, cross-sectional study conducted in 
Spain, used temperature data from the National Meteorology Agency from 1971-2000; 
clinical, demographic and lifestyle surveys; physical exams; and blood sampling to 
assess the association between ambient temperature and obesity.75 After controlling for 
demographic and lifestyle variables, there was a statistically significant positive 
association between ambient temperature and obesity, with higher ambient temperature 
positively correlated to higher obesity levels.  Higher ambient temperature has also 
been associated with significantly lower circulating HDL and higher circulating LDL.76 In 
this study, temperature did not correlate with circulating triglyceride or total cholesterol 
levels.  However, a prior experimental study did demonstrate that elevated temperature 
caused a 14% increase in plasma cholesterol.76,77  Conversely, other research suggests 
fasting blood glucose and blood pressure are inversely related to temperature.78,79 
  
Giorgini and colleagues (2015) used a cross-sectional observational study to determine 
whether short-term ambient PM2.5 and temperature had an effect on cardiopulmonary 
exercise test results of 2078 patients undergoing cardiac rehabilitation at the University 
of Michigan.74 The researchers found that short-term PM2.5 and temperature elevations 
were associated with poorer aerobic exercise capacity. This result supports the 
hypothesis that elevated temperature, like PM, can worsen underlying cardiovascular 
disease. 
  
Temperature may impact metabolic syndrome risk through adipose tissue’s role in body 
temperature homeostasis. When temperature decreases, adipocytes release fatty acids 
to generate heat and maintain body temperature.  Specifically, brown adipose tissue is 
involved in burning energy to produce heat. Brown adipose tissue appears to regulate 
whole-body metabolism and may improve insulin sensitivity and decrease weight gain 
risk.80 Evidence suggests that individuals with a greater percentage of brown adipose 
tissue are protected from diabetes mellitus and obesity.41,80,81,82 Outdoor air temperature 
has been negatively associated with the amount and glucose-uptake activity of brown 
adipose tissue.41 Therefore, those who are exposed to relatively warmer temperatures 
burn fewer calories to maintain their body temperature; have a lower percent of brown 
adipose tissue; and may be at greater risk for metabolic syndrome. 
  
Purpose and Importance of the Present Study 
Despite the intriguing data presented above, the possible relationship of local PM2.5 
levels and temperature with metabolic syndrome is still under-investigated in human 
populations. Previous epidemiology studies have investigated the relationship of single 
exposures with individual metabolic components, rather than with the entire complex of 
metabolic alterations that compose metabolic syndrome.75,76,83,84,85  Furthermore, 
previous human studies have mainly focused on the associations between short-term 
temperature exposure and metabolic outcomes, which may reflect transient 
modifications that are not necessarily related to long-term risks.76,77  To date, no studies 
reported an incident analysis on the topic. 
  
The current study prospectively examined the association of the average levels of 
ambient PM2.5 and temperature at the participant’s address with the development of 
metabolic syndrome, as well as with the individual conditions that compose metabolic 
syndrome. We leveraged prospective data from Veteran Affairs (VA) Normative Aging 
Study (NAS) participants, a cohort of older men living across Eastern Massachusetts; 
Southern New Hampshire; and Southern Maine. We hypothesized that exposure to 
higher levels of PM2.5 ambient air pollution would increase the risk of developing 
metabolic syndrome. The longitudinal, prospective design of this study has the potential 
to produce strong evidence for a causal link between pollution exposure and metabolic 
syndrome, because pollution exposure can be shown to predate the metabolic 
syndrome phenotype. This research could help inform future policy decisions regarding 
environmental pollution regulations and help target public health interventions to those 
individuals most at risk of developing metabolic syndrome. 
 
METHODS  
Study population  
The present analysis included 587 men who were active participants in the longitudinal 
NAS between 1993-2011 (Table 2).86 All participants included in the analysis were free 
of metabolic syndrome at the first visit (baseline) during the study period and received 
comprehensive outpatient medical evaluations every 3-7 years. During the visits, 
participants provided detailed information about their lifestyle, dietary habits, activity 
levels and demographic factors. In each diagnosis-specific analysis, we excluded 
participants who met pathological criteria for that disorder at the baseline visit (Table 2, 
Table 3). All participants gave written informed consent in accordance with the VA 
Boston Healthcare System Institutional Review Board and the Institutional Review 
Boards of all participating institutions.  
 
Spatio-temporal resolved modeling of particulate matter (PM) level  
To assign exposure we used a recently published validated spatiotemporal hybrid 
model, developed by our research group, to estimate daily PM2.5 level (in µg/m3) across 
the study area.87 We used the average PM2.5 level during the year prior to each visit at 
each participant’s residential address to assess the long-term association of air pollution 
with metabolic dysfunction. The model incorporates previously reported fine scale local 
land use regression and satellite aerosol optical depth.87 This hybrid model provides 
address-level resolution for long-term PM2.5 measurements collected between May 
2000 and December 2011. Due to limitations in data availability, we used a similar 
hybrid satellite based Moderate Resolution Imaging Spectroradiometer (MODIS) model 
albeit at a lower spatial resolution of 10x10 km grid for May 2000-October 2003 and on 
a 1x1 km grid for October 2003-December 2011.87,88 Missing observations on the 1x1 
km grid over the period October 2003-December 2011 were also replaced with 
measures from 10x10 km grid. Out-of-sample cross validation showed good fit of the 
10x10 km model (R2=0.81), and an excellent fit of 1x1 km the model (R2 = 0.87).87,88  
 
Time- and space-resolved modeling of temperature level  
We used the average daily temperature during the year before each visit at 1x1 km 
resolution as a proxy of the temperature at the participant’s address in order to assess 
the long-term association of outdoor temperature with metabolic dysfunction. Daily 
temperature with 1x1 km resolution was predicted using a spatio-temporally resolved 
satellite based model similar to that used for PM2.5.89,90 Daily estimates were averaged 
to produce annual average temperatures. A ten-fold out of sample cross validation was 
used to validate the accuracy of the predictions and it showed good fit (mean out-of-
sample R2 = 0.94).89,90  
 
Assignment of PM2.5 and temperature levels.  
In this analysis, we defined as baseline the first NAS visit conducted prior to May 2000, 
i.e., the first month with available PM2.5 and temperature estimates. We used as 
exposure metrics the average of PM2.5 or temperature levels at each participant’s 
address in the year before each subsequent follow-up visit, as a proxy for exposure 
between visits. The 1-year average was selected because it correlates well with 
averages of PM2.5 over longer time windows (e.g., 2-5 years) in this study population 
(Table 4) and was available for a higher number of visits than the 2-5 year averages, 
because it could be calculated for follow-up visits conducted between 2-5 years after the 
inception of the model used to estimate PM2.5.  
 
Clinical measures  
At each visit, anthropometric measures were performed with participants in undershorts 
and socks. Waist circumference was measured in centimeters at the umbilical level, 
perpendicular to the axis of the upper body.91 Participants were considered to have 
abdominal obesity if their waist circumference was $102 cm. At each visit, fasting blood 
glucose and lipid levels were measured on blood drawn on the morning of the medical 
evaluation. In keeping with metabolic syndrome diagnostic criteria, high blood sugar 
was defined as a fasting blood glucose $100 mg/dl or drug treatment for elevated blood 
glucose, low HDL was any value <40 mg/dl or drug treatment for low HDL cholesterol 
and hypertriglyceridemia was any triglyceride measure $150 mg/dl or drug treatment for 
elevated triglycerides. Individuals were diagnosed with hypertension if their systolic 
blood pressure $130 mm Hg or diastolic blood pressure was $85 mm Hg or they were 
taking drug treatment for elevated blood pressure. Participants who met three or more 
of the above diagnostic criteria for abdominal obesity, high fasting blood glucose, low 
HDL, hypertension or hypertriglyceridemia were considered to have metabolic 
syndrome.8,92 A structured in-person questionnaire was used to collect information 
about lifestyle and dietary habits, including physical activity, smoking status, alcohol 
consumption and average dark fish consumption.  
 
Statistical analysis  
The risk of future metabolic dysfunction associated with 1-year average ambient PM2.5 
or temperature estimated at the participant’s address was evaluated using the Cox 
proportional model. This method’s ability, to handle censored data and time-dependent 
covariates, makes it well suited for this analysis.93 Metabolic syndrome and five 
individual measures of metabolic function—waist circumference, fasting blood glucose, 
HDL cholesterol levels, blood pressure and triglycerides— were modeled separately.  
 
Each model included time dependent variables - the participant’s age at the time of the 
visit (continuous), dark fish consumption (<once a week, $once a week), alcohol 
consumption (<2 drinks/day, $2 drinks/day), smoking status (never, former, current) and 
physical activity (<12, 12|-30, $ 30 metabolic equivalent hours (MET-hr] per week) – and 
variables at the baseline visit – education as a proxy for socioeconomic status (<12, 
12|–|16, >16 years), an indicator for whether the participant was a part-time resident of 
the greater Boston area (yes/no), percentage of the participant’s census tract that is 
nonwhite (continuous). Statin, antihypertensive and diabetes medications were included 
in the model for metabolic syndrome as a whole and were considered as time 
dependent variables. PM2.5 models were adjusted for 1-year average temperature levels 
and vice-versa. Each model included strata for variables that did not meet the Cox 
proportional hazard assumptions. We additionally represented the significant 
associations and verified graphically that PM2.5 and temperature levels did not show 
major departures from the linear association with the outcomes (Figures 1-2).  
 
We also reanalyzed each PM2.5 model after restricting the analysis to observations with 
PM2.5 levels lower than 12 "g/m3, which is the primary annual fine particle standard set 
by U.S. Environmental Protection Agency for public health protection.94 As a sensitivity 
analysis, we excluded outliers for PM2.5 and temperature levels for all models and we 
excluded physical activity from the list of covariates, because including them may have 
resulted in over-adjustment.  We further investigated the interaction between air 
pollution and ambient temperature in relation to metabolic syndrome and its individual 
components.  We additionally evaluated changes in each cardio-metabolic measure 
over time relative to air pollution and temperature using linear model with repeated 
observations for each participant. The analysis was subsequently stratified for 
participants with and without metabolic syndrome at the baseline.  We used SAS® 
statistical package version 9.3 (Copyright, SAS Institute Inc. SAS and all other SAS 
Institute Inc. product or service names are registered trademarks or trademarks of SAS 
Institute Inc., Cary, NC, USA) and R for all models.95,96,97  
 
RESULTS  
Descriptive statistics  
Table 3 shows demographic and clinical data for all participants. At baseline, out of the 
587 NAS participants 191 (33%) had abdominal obesity, 294 (50%) had high blood 
glucose, 261 (44%) had low HDL, 471 (80%) had hypertension, 271 (46%) had 
hypertriglyceridemia and 316 (53%) met metabolic syndrome criteria and were excluded 
from the corresponding analysis. Participants were 70 years old on average at baseline 
and attended up to 6 visits (average = 2.2). Most participants were Caucasian (88%), 
had at least a college degree (71%) and were permanent residents of the greater 
Boston area (86%). Most men reported low physical activity (58%), light or lower alcohol 
consumption (77%) and were former smokers (65%). Twenty-four percent of the 
participants used statins, 5% used diabetes drugs, and 49% used antihypertensive 
medications. Percentage of prescribed medications and number of participants varied 
across the data subsets used for analysis of individual metabolic syndrome 
components.  
 
Ambient air pollution and temperature associations  
Estimated PM2.5 levels ranged between 4.2- 13.6 µg/m3 (mean (SD), 10.5 (1.4) µg/m3). 
A 1 µg/m3 annual PM2.5 increase was significantly associated with a 27% increased risk 
of developing metabolic syndrome (Hazard Ratio (HR) = 1.27; 95% Confidence Interval 
(CI): 1.06, 1.52, P=0.01), as well as some of its components, i.e. 20% increased risk of 
developing elevated fasting blood glucose (HR = 1.20; 95% Confidence Interval (CI): 
1.03, 1.39, P=0.02), and a 14% increased risk of hypertriglyceridemia (HR = 1.14, 95% 
CI: 1.00, 1.30, P=0.05) (Table 5, Figure 1). Estimated annual temperature levels ranged 
between 7.5-18.8 Cº (mean (SD), 11.4 (1.1) Cº). A 1 Cº annual temperature increase 
was associated with a 33% increased elevated fasting blood glucose risk (HR = 1.33, 
CI: 1.14, 1.56, P<0.001) (Table 5, Figure 2). However, temperature level was not 
significantly associated with the risk of metabolic syndrome as a whole (HR = 0.99, 95% 
CI: 0.82, 1.21, P=0.95).  
 
After restricting the analysis only to observations with 1-year average PM2.5 less than 12 
"g/m3 (Table 6), PM2.5 results for the metabolic syndrome and high fasting blood 
glucose analyses remained significant and showed stronger associations, i.e. 40% 
increased risk of developing metabolic syndrome (HR = 1.40, CI: 1.11, 1.77, P=0.005) 
and 31% increased risk of elevated fasting blood glucose (HR = 1.31, CI: 1.05, 1.63, 
P=0.02).  
 
The 1-year average PM2.5 and temperature included outliers, defined as having an 
absolute deviation of three standard deviations from the mean. Analysis excluding the 
33 outliers confirmed results for PM2.5 and temperature on metabolic syndrome and 
fasting blood glucose (Table 7). Only HDL Cholesterol levels were (negatively) 
associated over time with temperature levels (Table 8).  
 
Results from analysis excluding physical activity from the list of covariates were 
consistent with previous findings (Table 9). Additionally there were no significant 
interactions between PM and temperature in any of the models (Table 10). 
 Increased temperature was significantly associated with increasing waist circumference 
over time (Table 8).  
 
DISCUSSION  
The present study showed associations of long-term exposure to ambient PM2.5 and 
outdoor temperature levels with increased risk of developing several components of 
metabolic dysfunction. PM2.5 was associated with increased risk of metabolic syndrome 
and some of its individual metabolic components, i.e., elevated fasting blood glucose 
and triglycerides; temperature was associated with increased elevated fasting blood 
glucose risk. To our knowledge, this is the first study that prospectively examined both 
PM2.5 and temperature exposure in relation to risk of metabolic syndrome, as well as of 
its individual components. Our results indicate that individuals who lived in 
neighborhoods with worse air quality, as reflected in higher PM2.5 levels, and/or that 
were warmer than average, had a greater risk of developing metabolic syndrome 
components. The associations of PM2.5 with metabolic syndrome and fasting blood 
glucose remain significant when restricting the analysis to observations below the U.S. 
Environmental Protection Agency’s threshold for primary annual fine particles. This 
finding may support the need for more stringent measures to further reduce PM2.5 
levels, as well as to begin considering ambient temperature—an environmental variable 
that has become key for climate change predictions—as a novel risk factor for long term 
metabolic risk.  
 
Our results are consistent with recent research into the biological mechanisms through 
which high levels of PM2.5 and temperature exposure may affect metabolic regulation. 
PM2.5 exposure may predispose individuals to metabolic dysfunction through the 
generation of oxygen free radicals, which can disrupt insulin signaling and impair 
vasorelaxation, thus contributing to insulin resistance and vascular disease.98,99 PM2.5 
has recently been shown to increase reactive oxygen species (ROS), which have been 
associated with metabolic dysfunction.100,101,102 Additionally, PM2.5 exposure may 
contribute to metabolic syndrome risk by activating cell signaling pathways implicated in 
metabolic dysfunction. Sun et al. (2009) demonstrated that long-term PM2.5 exposure 
leads to systemic inflammation, increased visceral adiposity and insulin resistance in 
male mice on a high fat diet.58 Air pollution exposure caused several signaling 
abnormalities associated with insulin resistance in the mice, including decreased 
Akt/protein kinase B and endothelial nitric oxide synthase phosphorylation in endothelial 
cells and elevated protein kinase C expression. The same group showed that long-term 
PM2.5 exposure causes up-regulation of genes involved in lipogenesis, lipolysis, 
adipocyte differentiation and lipid droplet formation in mouse adipose tissue.59 These 
studies are highly supportive of our findings and suggest possible mechanisms for 
PM2.5-induced metabolic dysfunction. Future research should further explore the 
mechanisms by which PM2.5 exposure induces metabolic dysfunction in humans and 
whether interventions to attenuate the response mitigate metabolic syndrome risk.   
  
The temperature-high-blood-sugar relationship that we identified may be due to adipose 
tissue’s role in adapting to temperature differences, which is consistent with prior 
obesity research.103 Indeed, in the presence of colder temperature, fat stored in 
adipocytes is mobilized and used to produce heat to keep body temperature constant. 
Brown adipose tissue, in particular, burns energy and glucose to generate heat and 
individuals with higher proportions of brown adipose tissue are protected from diabetes 
and obesity.41,80,81,82 Individuals exposed to comparatively higher temperatures burn 
fewer calories to maintain body temperature, have less brown adipose tissue, and 
therefore, as shown in our analysis, may be more prone to developing insulin 
resistance.  
 
Interestingly, neither PM2.5 nor temperature was significantly associated with abdominal 
obesity, low HDL cholesterol or hypertension, key components of metabolic syndrome 
that are often presented as underlying and/or preceding the other components and 
cardiovascular morbidity.104,105,106 This finding may be due to the high prevalence of 
those conditions already present at the baseline and/or it may indicate that PM2.5 and 
temperature activate metabolic mechanisms, such as inflammation, which might 
increase the risk of elevated fasting blood glucose and hypertriglyceridemia without 
substantially increasing the risk of abdominal obesity, low HDL cholesterol and 
hypertension. On the other hand, the lack of association with abdominal obesity indicate 
that our findings were not confounded by possible correlations with obesity-associated 
lifestyles, such as those resulting in high calorie diet or low physical activity, which 
would be expected to also significantly increase obesity risk.  
 
In the present study, the estimated effect size of the association between PM2.5 and 
metabolic syndrome is relatively larger than other studies of cardiovascular events or 
death. Older individuals are especially susceptible to pollution-triggered morbidity and 
mortality.107  The risk of developing metabolic syndrome increases with age. Metabolic 
syndrome affects approximately 24% of the US adult population, and the prevalence 
increases dramatically in older adults ($ 50 year/old) to 44%.16,92 Therefore, the 
Normative Aging Study participants represent a particularly vulnerable population, as it 
is composed of older male participants (average age of 70 years, SD=7). Previous 
studies suggested that metabolic syndrome is a precursor for coronary heart disease, 
and it contributes to the risk of cardiovascular mortality.108,109 Increased risk for 
developing metabolic syndrome in response to air pollution might serve as one of the 
primary intermediate outcomes contributing to air pollution-related cardiovascular 
disease events.16 We used validated space- and time-resolved models to estimate 
PM2.5 at each participant’s home address and temperature with 1x1 km resolution. All 
the NAS participants lived in the same metropolitan area, which is relatively cool and 
with a low penetrance of air conditioning.110 However, 1-year averages of both PM2.5 
and temperature levels showed wide variations across participants, mostly due to 
differences in residential address characteristics such as proximity to roadways or 
water, and amounts of green space and concrete. In our study, we were also able to 
control for variables related to personal and residence-based characteristics, which 
should limit residual confounding by those factors. Finally, our results included a 
substantial number of observations; each of our 587 participants completed 2.2 study 
visits on average.  
 
Some limitations could affect our study. The study sample is over 88% white and all 
male, which limits the generalizability of our results to other races and to women.  Other 
possible sources of bias should be considered in the interpretation of our results, 
including the use of exposure estimates based on residential address of 1x1 km 
resolution, which may misclassify personal exposure levels. Measurement error of air 
pollution and temperature is a common limitation of epidemiologic studies, which usually 
leverage PM2.5 and temperature measurements of ambient particulate concentrations 
and temperature, respectively, from stationary monitors to obtain estimates of study 
participants’ exposure. The difference between the ambient estimate and a participant’s 
average personal exposure is a potentially important source of bias, for both air 
pollution and temperature measures. This bias is unlikely to alter our conclusions on 
statistically significant findings, because using the ambient concentration 
misclassification is most likely to attenuate statistical associations.111 It is possible, 
however, that measurement error is responsible for the lack of association observed 
with some metabolic components. Additionally, participants likely control the 
temperature inside their homes and may not have much exposure to ambient air 
temperature, which could also attenuate our temperature findings. Furthermore, 
because the NAS is a largely retired cohort, level estimates at the participant's’ address 
or with 1x1 km resolution are expected to correlate well with personal exposures due to 
the lack of commuting to work.112  
 
SUMMARY  
Our results add evidence that long-term PM2.5 and temperature exposures increase 
metabolic dysfunction risk. People living in neighborhoods with worse air quality, in 
terms of higher PM2.5 levels, and/or warmer than average, showed an increased risk of 
developing metabolic dysfunctions. These metabolic associations may represent 
intermediates to explain the link between increased exposure to PM2.5 and higher 
temperature with cardiovascular morbidity and long-term mortality risks. Our findings 
may indicate the need for more stringent control of ambient PM2.5 levels and for revising 
estimates of the health impact of climate changes to account for long-term risk of 
metabolic dysfunction and its sequelae. 
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Table 1.Clinical Identification of the Metabolic Syndrome and its Components and Number of Events Over Time in the 
Analysis. 
 
ATP III/NHLBI Clinical Identification Cut point Number of  events 
Abdominal Obesity  !102 cm (men) 107 
High Fasting Blood Glucose  !100 mg/dL or medication 118 
Low HDL cholesterol  <40 mg/dL (men) or medication 165 
Hypertension !130/!85 mm Hg or medication 82 
Hypertriglyceridemia ! 150 mg/dL or medication 154 
Metabolic Syndrome  any 3 of the previous 140 
Abbreviations: HDL: High-density Lipoprotein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Eligible and Non-Eligible Participants in NAS Data With at Least one Measurement on and After May 
2000. 
Units Selected from Sampling Frame Number of participants 
Respondent, total 759 
Eligible respondent with missing measures or data  
Participants with only 1 visit and/or disease at the first visit 95 
Missing covariates 15 
Missing PM2.5 estimates 56 
Missing temperature estimates 6 
Eligible respondents with non-missing data for main analysis, total 587 
Abbreviations: PM2.5: Particulate matter with diameter under 2.5 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Descriptive Statistics at the Baseline Visit, According to the Metabolic Syndrome and its Individual Components. 
 Analysis Entire population 
Subsets used in each analysis 
Abdominal 
Obesity 
High 
Fasting 
Blood 
Glucose 
Low HDL 
Cholesterol Hypertension 
Hypertrigly
ceridemia 
Metabolic 
Syndrome 
Number of participants 587 396 293 326 116 316 271 
Number of excluded 
participants   191 294 261 471 271 316 
Number of visit, Mean 
(Max) 2.2 (6) 2.3 (6) 2.1 (6) 2.1 (6) 2.1 (6) 2.1 (6) 2.1 (6) 
Age, Mean (SD) 70.4 (6.9) 70.8 (6.8) 70.5 (6.9) 70.5 (7.1) 68.4 (7.6) 70.8 (7.1) 70.4 (7.3) 
Nonwhite (% of census 
tract), Mean (SD) 11.9 (13) 12 (12.6) 11.2 (11.9) 12.5 (13.6) 10.8 (11.6) 12.2 (13.3) 12.1 (12.9) 
Education (years), N (%) 
!12 years 171 (29.13) 116 (29.29) 86 (29.35) 89 (27.3) 33 (28.45) 86 (27.22) 72 (26.57) 
12-16 years 294 (50.09) 196 (49.49) 138 (47.10) 166 (50.92) 54 (46.55) 161 (50.95) 134 (49.45) 
>16 years 122 (20.78) 84 (21.21) 69 (23.55) 71 (21.78) 29 (25.00) 69 (21.84) 65 (23.99) 
Physical Activity (MET-hr/week), N (%) 
<12 342 (58.26) 206 (52.02) 152 (51.88) 192 (58.9) 59 (50.86) 191 (60.44) 140 (51.66) 
12–30 149 (25.38) 111 (28.03) 87 (29.69) 86 (26.38) 42 (36.21) 79 (25.00) 85 (31.37) 
"30 96 (16.35) 79 (19.95) 54 (18.43) 48 (14.72) 15 (12.93) 46 (14.56) 46 (16.97) 
Smoking status, N (%)        
Never 169 (28.79) 121 (30.56) 95 (32.42) 94 (28.83) 36 (31.03) 94 (29.75) 87 (32.1) 
Former 384 (65.42) 253 (63.89) 184 (62.8) 211 (64.72) 69 (59.48) 202 (63.92) 165 (60.89) 
Current 34 (5.79) 22 (5.56) 14 (4.78) 21 (6.44) 11 (9.48) 20 (6.33) 19 (7.01) 
Alcohol Consumption, N(%) 
(<2 drinks/day) 453 (77.17) 311 (78.54) 230 (78.50) 235 (72.09) 92 (79.31) 243 (76.9) 206 (76.01) 
("2 drinks/day) 134 (22.83) 85 (21.46) 63 (21.50) 91 (27.91) 24 (20.69) 73 (23.10) 65 (23.99) 
Table 3 continues on the following page 
 
 
 
 
Table 3 continues from the previous page 
Consumed Dark Fish (times/week), N (%) 
<1 507 (86.37) 335 (84.60) 245 (83.62) 285 (87.42) 99 (85.34) 270 (85.44) 231 (85.24) 
"1 80 (13.63) 61 (15.40) 48 (16.38) 41 (12.58) 17 (14.66) 46 (14.56) 40 (14.76) 
Not Permanent Resident, N (%) 
No 514 (87.56) 346 (87.37) 254 (86.69) 286 (87.73) 100 (86.21) 280 (88.61) 237 (87.45) 
Yes 73 (12.44) 50 (12.63) 39 (13.31) 40 (12.27) 16 (13.79) 36 (11.39) 34 (12.55) 
Statin intake, N(%)        
No 449 (76.49) 288 (72.73) 217 (74.06) 326 (100) 91 (78.45) 316 (100) 262 (96.68) 
Yes 138 (23.51) 108 (27.27) 76 (25.94) 0 (0) 25 (21.55) 0 (0) 9 (3.32) 
Diabetes medicine intake, N(%)  
No 560 (95.40) 379 (95.71) 293 (100) 316 (96.93) 114 (98.28) 307 (97.15) 268 (98.89) 
Yes 27 (4.60) 17 (4.29) 0 (0) 10 (3.07) 2 (1.72) 9 (2.85) 3 (1.11) 
Hypertensive medicine intake, N(%)  
No 300 (51.11) 209 (52.78) 166 (56.66) 185 (56.75) 116 (100) 177 (56.01) 179 (66.05) 
Yes 287 (48.89) 187 (47.22) 127 (43.34) 141 (43.25) 0 (0) 139 (43.99) 92 (33.95) 
Abbreviations: HDL: High-density Lipoprotein; Max: Maximum; N: Number; SD: Standard Deviation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Correlation Coefficients Between 1-Year PM2.5 Exposure Levels and PM2.5 Exposure Levels With Different 
Time Windows. 
Exposure level  Pearson Correlation coefficients with PM2.5 1-year P a 
Number of 
observations 
PM2.5 1 year   1811 
PM2.5 2 years 0.94 <.0001 990 
PM2.5 3 years 0.91 <.0001 854 
PM2.5 4 years 0.87 <.0001 702 
PM2.5 5 years 0.86 <.0001 619 
Abbreviations: PM2.5: Particulate matter with diameter under 2.5 µm. 
a Two sided P. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: Association of 1-year PM2.5a and Temperatureb Levels exposure with Risk of Individual Components and Composite 
Diagnosis of Metabolic Syndrome.  
Association with 
N 
partici
pants 
N 
observ
ations 
N 
events 
  PM2.5   Temperature 
  Hazard Ratio 95% CI P
 e    Hazard Ratio 95% CI P
 e  
Abdominal Obesityc 396 857 107   1.00 (0.86, 1.16) 1.00   1.06 (0.86, 1.31) 0.58 
High Fasting Blood Glucosec 293 562 118   1.20 (1.03, 1.39) 0.02   1.33 (1.14, 1.56) <0.001 
Low HDL Cholesterolc 326 625 165   0.98 (0.85, 1.13) 0.76   1.01 (0.85, 1.20) 0.90 
Hypertensionc 116 207 82   1.20 (0.97, 1.49) 0.09   1.14 (0.86, 1.50) 0.37 
Hypertriglyceridemiac 316 598 154   1.14 (1.00, 1.30) 0.05   1.07 (0.92, 1.24) 0.36 
Metabolic Syndromec,d  271 517 140   1.27 (1.06, 1.52) 0.01   0.99 (0.82, 1.21) 0.95 
Abbreviations: 95%CI: 95% Confidence Interval; HDL: High-density Lipoprotein; N: Number; PM2.5: Particulate matter with 
diameter under 2.5 µm. 
 
a PM2.5 (for each 1 ug/m3) was 1-year average from daily estimates including AOD data from the 1x1 km  model and 10x10 km  
model.  
b Temperature (for each 1ºC) was 1-year average from daily estimates including AOD data from the 1x1 km  model.  
c Variables included in the model: time dependent variables-age at the visit (continuous), dark fish consumption (<once a week, !once 
a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (current, former, never), physical activity (<12, 12|-30, ! 
30 metabolic equivalent hours (MET-hr) per week)- and variables at the baseline-education (<12, 12|–|16, >16 years), an indicator for 
whether the participant was a part-time resident of the greater Boston area (yes/no), percentage of the participant’s census tract that is 
nonwhite (continuous).  
d Included medications varying over time: diabetes medication (no/yes),  statin (no/yes) and  antihypertensive medication(no/yes). 
e Two sided P. 
 
 
 
 
Table 6: Association of 1-Year PM2.5a Levels with Risk of Individual Components and Composite Diagnosis of Metabolic 
Syndrome in Observations with PM2.5 Levels Lower Than 12 #g/m3.  
Association with N participants 
N 
observations 
N 
events 
  PM2.5 
  Hazard Ratio 95% CI P d  
Abdominal Obesity b 368 753 102   1.12 (0.94, 1.34) 0.21 
High Fasting Blood Glucose b 261 484 101   1.31 (1.05, 1.63) 0.02 
Low HDL Cholesterol b 287 536 141   0.98 (0.83, 1.16) 0.85 
Hypertension b 101 179 67   1.36 (0.81, 2.29) 0.24 
Hypertriglyceridemia b 282 515 135   1.14 (0.96, 1.35) 0.12 
Metabolic Syndrome b,c 243 441 125   1.40 (1.11, 1.77) 0.005 
Abbreviations: 95%CI: 95% Confidence Interval; HDL: High-density Lipoprotein; N: Number; PM2.5: Particulate matter with 
diameter under 2.5 µm. 
 
a PM2.5 (for each 1 ug/m3) was 1-year average from daily estimates including AOD data from the 1x1 km  model and 10x10 km  
model.  
b Variables included in the model: time dependent variables-age at the visit (continuous), dark fish consumption (<once a week, !once 
a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (current, former, never), physical activity (<12, 12|-30, ! 
30 metabolic equivalent hours (MET-hr) per week), 1-year average temperature levels- and variables at the baseline-education (<12, 
12|–|16, >16 years), an indicator for whether the participant was a part-time resident of the greater Boston area (yes/no), percentage of 
the participant’s census tract that is nonwhite (continuous).  
c Included medications varying over time: diabetes medication (no/yes),  statin (no/yes) and  antihypertensive medication(no/yes). 
d Two sided P. 
 
 
 
 
 
Table 7. Sensitivity Analysis Excluding Outliers for PM2.5 and Temperature. Effect of 1-Year PM2.5a and Temperatureb Levels 
Exposure on Risk of Individual Components and Composite Diagnosis of Metabolic Syndrome in NAS Participants Since May 
2000. 
Effect on N participants 
N 
observations 
N 
events 
  PM2.5   Temperature 
  Hazard Ratio 95% CI P
 e   Hazard Ratio 95% CI P
 e 
Abdominal Obesityc 390 834 107   0.99 (0.85, 1.15) 0.88   1.12 (0.88, 1.42) 0.36 
High Fasting Blood Glucosec 287 547 113   1.23 (1.05, 1.44) 0.01   1.38 (1.12, 1.71) 0.003 
Low HDL cholesterolc 317 603 161   1.00 (0.86, 1.15) 0.95   1.06 (0.85, 1.31) 0.61 
Hypertensionc 112 200 79   1.18 (0.95, 1.47) 0.14   1.03 (0.74, 1.44) 0.84 
Hypertriglyceridemiac 303 571 147   1.18 (0.98, 1.42) 0.09   1.23 (0.93, 1.63) 0.14 
Metabolic Syndromec,d 263 498 135   1.50 (1.07, 2.09) 0.02   1.06 (0.71, 1.60) 0.77 
Abbreviations: 95%CI: 95% Confidence Interval; HDL: High-density Lipoprotein; N: Number; PM2.5: Particulate matter with 
diameter under 2.5 µm. 
 
a PM2.5 (effect for each 1 ug/m3) was 1-year average from daily estimates including AOD data from the 1x1 km  model and 10x10 km  
model.  
b Temperature (effect for each 1ºC) was 1-year average from daily estimates including AOD data from the 1x1 km  model.  
c variables included in the model: time dependent variables-age at the visit (continuous), dark fish consumption (<once a week, !once 
a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (current, former, never), physical activity (<12, 12|-30, ! 
30 metabolic equivalent hours (MET-hr) per week)- and variables at the baseline-education (<12, 12|–|16, >16 years), an indicator for 
whether the participant was a part-time resident of the greater Boston area (yes/no), percentage of the participant’s census tract that is 
nonwhite (continuous).  
d included medications varying over time: diabetes medication (no/yes),  statin (no/yes) and  antihypertensive medication(no/yes). 
e Two sided P. 
 
 
 
 
 
Table 8: Association of 1-year PM2.5a and Temperatureb Levels exposure with the Change Over Time in the Individual Conditions of the 
Metabolic Syndrome for all participants (N=587) and Progression of Each Condition for Participants With and Without the Metabolic 
Syndrome at the Baseline. 
Association   All participants (N=587)   
On participants without 
metabolic syndrome at the 
baseline (N=271) 
  
On participants with 
metabolic syndrome at the 
baseline (N=316)   
P* for 
interaction 
Est. 95% CI P*    Est. 95% CI P*    Est. 95% CI P*    
PM2.5       
 
              
 
  
 
Waist circumferencec 2.05 (-1.22; 5.32) 0.22  1.60 (-1.66; 4.85) 0.34  1.74 (-1.05; 5.75) 0.18  0.24 
 
Fasting Blood Glucosec,d 0.10 (-0.44; 0.65) 0.71  -0.19 (-0.74; 0.35) 0.49  0.28 (-0.27; 0.83) 0.32  0.004 
 
HDL Cholesterolc,e 0.16 (-0.17; 0.49) 0.35  0.07 (-0.32; 0.47) 0.71  0.17 (-0.16; 0.51) 0.30  0.28 
 
Systolic Blood Pressurec,f 0.34 (-0.16; 0.84) 0.18  0.36 (-0.17; 0.89) 0.18  0.27 (-0.19; 0.87) 0.20  0.83 
 
Diastolic Blood Pressurec,f 0.16 (-0.17; 0.49) 0.35  0.25 (-0.1; 0.6) 0.16  0.18 (-0.22; 0.47) 0.48  0.26 
 
Triglyceridesc,e -0.74 (-2.90; 1.42) 0.50   -1.14 (-3.18; 0.91) 0.28   1.12 (-2.76; 1.62) 0.61  0.42 
               Temperature 
     
  
      
 
Waist circumferencec 5.22 (0.05; 10.39) 0.05  5.02 (0.07; 9.97) 0.05  2.68 (-0.76; 9.74) 0.09  
0.47 
 
Fasting Blood Glucosec,d 0.01 (-0.92; 0.93) 0.99  0.02 (-0.8; 0.84) 0.96  0.46 (-1.31; 0.49) 0.37  
0.004 
 
HDL Cholesterolc,e 0.28 (-0.23; 0.80) 0.28  0.22 (-0.32; 0.77) 0.43  0.32 (-0.41; 0.83) 0.51  
0.87 
 
Systolic Blood Pressurec,f -0.53 (-1.34; 0.28) 0.20  -0.51 (-1.33; 0.31) 0.22  0.44 (-1.38; 0.35) 0.24  
0.73 
 
Diastolic Blood Pressurec,f -0.07 (-0.72; 0.57) 0.82  -0.02 (-0.64; 0.61) 0.96  0.32 (-0.58; 0.65) 0.91  
0.71 
 Triglyceridesc,e -0.56 (-3.01; 1.89) 0.66   -0.81 (-3.17; 1.56) 0.50   1.23 (-3.45; 1.37) 0.40  0.79 
Abbreviations: 95%CI: 95% Confidence Interval; Est: Estimate, HDL: High-density Lipoprotein, PM2.5: Particulate matter with diameter < 2.5µm.  
* Two sided P. 
 
a PM2.5 (for each 1 ug/m3) was 1-year average prior the baseline visit from daily estimates including AOD data from the 1x1 km  model and 10x10 
km  model.  
b Temperature (for each 1ºC) was 1-year average prior the baseline visit from daily estimates including AOD data from the 1x1 km  model.  
c Variables included in the model: time dependent variablesthe participant’s age at the time of the visit (continuous), dark fish consumption (<once 
a week, !once a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (never, former, current) and physical activity (<12, 
12|-30, ! 30 metabolic equivalent hours [MET-hr] per week) – and variables at the baseline visit – education as a proxy for social economic status 
(<12, 12|–|16, >16 years), an indicator for whether the participant was a part-time resident of the greater Boston area (yes/no), percentage of the 
participant’s census tract that is nonwhite (continuous).  
d Included medications varying over time: diabetes medication (no/yes). 
e Included medications varying over time: statin (no/yes). 
f Included medications varying over time: antihypertensive medication(no/yes). 
 
 
Table 9: Association of 1-year PM2.5a and Temperatureb Levels exposure with Risk of Individual Components and Composite 
Diagnosis of Metabolic Syndrome, Excluding the Physical Activity variable. 
Association with N participants 
N 
obs 
N 
events 
  N (%) 
obs 
Modera
te PA 
N (%) 
obs 
High 
PA  
  PM2.5   Temperature 
    Hazard Ratio 95% CI P
 e    Hazard Ratio 95% CI P
 e  
Abdominal Obesityc 396 857 107   229 (26) 165 (19)   1.01 (0.88; 1.17) 0.85   1.03 (0.84; 1.27) 0.77 
High Fasting Blood Glucosec 293 562 118   157 (27) 110 (19)   1.20 (1.03; 1.40) 0.02   1.30 (1.12; 1.52) 0.001 
Low HDL Cholesterolc 326 625 165   161 (25) 95 (15)   1.03 (0.89; 1.20) 0.66   1.03 (0.86; 1.25) 0.74 
Hypertensionc 116 207 82   73 (35) 31 (15)   1.19 (0.96; 1.48) 0.11   1.14 (0.87; 1.49) 0.33 
Hypertriglyceridemiac 316 598 154   150 (24) 87 (14)   1.14 (1,00; 1.30) 0.04   1.06 (0.91; 1.22) 0.46 
Metabolic Syndromec,d  271 517 140   151 (28) 95 (18)   1.28 (1.03; 1.58) 0.02   1.03 (0.82; 1.29) 0.80 
Abbreviations: 95%CI: 95% Confidence Interval; HDL: High-density Lipoprotein; N: Number; PA: Physical Activity; PM2.5: 
Particulate matter with diameter under 2.5 µm. 
 
a PM2.5 (for each 1 ug/m3) was 1-year average from daily estimates including AOD data from the 1x1 km  model and 10x10 km  
model.  
b Temperature (for each 1ºC) was 1-year average from daily estimates including AOD data from the 1x1 km  model.  
c Variables included in the model: time dependent variables-age at the visit (continuous), dark fish consumption (<once a week, !once 
a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (current, former, never) - and variables at the baseline-
education (<12, 12|–|16, >16 years), an indicator for whether the participant was a part-time resident of the greater Boston area 
(yes/no), percentage of the participant’s census tract that is nonwhite (continuous).  
d Included medications varying over time: diabetes medication (no/yes),  statin (no/yes) and  antihypertensive medication(no/yes). 
e Two sided P. 
 
  
 
Table 10: Association of interaction term of 1-year PM2.5a and Temperatureb Levels exposure with Risk of Individual 
Components and Composite Diagnosis of Metabolic Syndrome.  
Association with N participants 
N 
observations 
N 
events 
  Interaction Temperature-PM2.5  
  Hazard Ratio 95% CI P e  
Abdominal Obesityc 396 857 107   0.94 (0.81; 1.1) 0.44 
High Fasting Blood Glucosec 293 562 118   0.97 (0.84; 1.12) 0.70 
Low HDL Cholesterolc 326 625 165   0.99 (0.87; 1.12) 0.87 
Hypertensionc 116 207 82   1.15 (0.93; 1.42) 0.18 
Hypertriglyceridemiac 316 598 154   1.02 (0.91; 1.15) 0.70 
Metabolic Syndromec,d  271 517 140   0.96 (0.81; 1.13) 0.62 
Abbreviations: 95%CI: 95% Confidence Interval; HDL: High-density Lipoprotein; N: Number; PM2.5: Particulate matter with 
diameter under 2.5 µm. 
 
a PM2.5 (for each 1 ug/m3) was 1-year average from daily estimates including AOD data from the 1x1 km  model and 10x10 km  
model.  
b Temperature (for each 1ºC) was 1-year average from daily estimates including AOD data from the 1x1 km  model.  
c Variables included in the model: time dependent variables-age at the visit (continuous), dark fish consumption (<once a week, !once 
a week), alcohol consumption (<2 drinks/day, !2 drinks/day), smoking status (current, former, never), physical activity (<12, 12|-30, ! 
30 metabolic equivalent hours (MET-hr) per week)- and variables at the baseline-education (<12, 12|–|16, >16 years), an indicator for 
whether the participant was a part-time resident of the greater Boston area (yes/no), percentage of the participant’s census tract that is 
nonwhite (continuous).  
d Included medications varying over time: diabetes medication (no/yes),  statin (no/yes) and  antihypertensive medication(no/yes). 
e Two sided P. 
 
 
 
 
 
 
 
 
 
Figure 1 Legend: Level of exposure to fine particulate matter PM2.5 and the hazard ratio for each individual component and 
composite diagnosis of metabolic syndrome in NAS participants since May 2000.  Abbreviations: 95%CI: 95% Confidence 
Interval; HDL: High-density Lipoprotein;  LOESS: locally weighted scatterplot smoothing; PM2.5: Particulate matter with diameter 
under 2.5 µm. 
 
 
 
 
 
Figure 2 Legend. Level of exposure to temperature and the hazard ratio for each individual component and composite 
diagnosis of metabolic syndrome in NAS participants since May 2000. Abbreviations: 95%CI: 95% Confidence Interval; HDL: 
High-density Lipoprotein;  LOESS: locally weighted scatterplot smoothing. 
 
 
